Joseph Mikhael, MD
JOSEPH MIKHAEL, MD, press conference moderator where these data were discussed, commented on the BEAT AML trial: “One of the greatest challenges in the concept of personalized medicine is that by the time you determine what is right for a patient [ie, genomic analysis], the horse is out of the barn, so to speak. You have to start treatment immediately or else the disease progresses quite rapidly. The enhanced collaboration along with artificial intelligence gives us answers more quickly. The window of opportunity of 7 days is important and improves upon cytogenetic analysis in the past. The objective is to shorten the time frame even more.” Dr. Mikhael is with Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix. ■
DISCLOSURE: Dr. Mikhael has received research funding from AbbVie, Celgene, Onyx, and Sanofi.
THE MULTIARM, multicollaborative BEAT AML umbrella trial demonstrated the feasibility of using next-generation sequencing to assign treatment tailored to individual genomics of elderly patients with acute myeloid leukemia (AML) within 7 days. This may prove to be a major advance, since typically...